Syncona Ltd GBP · LSE:SYNC
Syncona Ltd GBP — Syncona — H1 2022 Earnings Presentation
40 slides from Syncona Ltd GBP's earnings presentation, November 2021
Slide 1: Investing to extend and enhance human life
Investing to extend and enhance human life Interim results 2021 synconaltd.com Image Freeline labs, Stevenage
Slide 2: Cautionary statement
Cautionary statement This presentation has been prepared and published solely for informational purposes. Nothing contained in this presentation is intended to constitute an offer, invitation or inducement to engage in an investment activity. In this statement, "presentation" means this document tog
Slide 3: Progress in the half
Progress in the half Continued focus on hands-on, active engagement with a maturing portfolio with key milestones ahead Strong clinical progress across NAV of £1,152.8m, 171.7p per Decisive actions taken by our Positive momentum with our diversified portfolio share, total return of (11.4)% portfolio
Slide 4: Syncona model in action: a partnership approach to building global leaders
Syncona model in action: a partnership approach to building global leaders Found, Build, Fund model enables strategic influence to address and navigate issues as they arise in clinical development Found Strong relationships with academic founders and 18 companies founded management teams or invested
Slide 5: Portfolio update
Portfolio update
Slide 6: Bringing our expertise to bear across our clinical portfolio
Bringing our expertise to bear across our clinical portfolio A maturing portfolio with five clinical-stage companies navigating the risks inherent in clinical development CAR-T cell therapy: Pivotal study Systemic gene therapy: Systemic PhasePhase gene therapy: I/II I/II Focus on progressing pivotal
Slide 7: Bringing our expertise to bear across our clinical portfolio
Bringing our expertise to bear across our clinical portfolio A maturing portfolio with five clinical-stage companies navigating the risks inherent in clinical development Retinal gene therapy: Phase I/II TIL cell therapy: Phase I/II Selective IL-2 agonist: Phase I/II Continued positive data generati
Slide 8: Generation 3 poised for clinical entry with Generation 4 progressing at pace
Generation 3 poised for clinical entry with Generation 4 progressing at pace Significant momentum and progress across pre-clinical companies led by strong management teams − Set for clinical entry in Q1 CY2022 − Initiated a natural history study in − Progressing pre-clinical with CTA filed1 AMN deve
Slide 9: Upcoming clinical milestones
15 milestones by the end of CY2022 with the potential to drive value Clinical stage Pre-clinical stage Upcoming clinical milestones 2021 2022 2023 Q4 CY2021 AUTO 1 Phase Ib data Q4 CY2021; pivotal data mid CY2022 CY 2023 Target BLA filing Autolus – initial Phase Ib pivotal data in AUTO1/22 AUTO1 Pha
Slide 10: Harnessing iPSC immune cloaking and differentiation platform technology
Harnessing iPSC immune cloaking and Clade was founded by a world-class team of company builders differentiation platform technology to deliver and scientific innovators with an unparalleled expertise in ‘off-the-shelf’ cell therapies generating stem cell derived immune therapies Founded by CEO Dr. C
Slide 11: Financing strategy
malarclareviare strategy
Slide 12: Optimising our financing approach to deliver on our strategy
Optimising our financing approach to deliver on our strategy Providing our shareholders with exposure to a set of high growth companies, both private and public Our financing approach involves supporting our companies to take one of two core strategies: Solely fund companies 1 through pre-clinical B
Slide 13: Financial review
Financial review
Slide 14: Financial review
Financial review Clinical Pre-clinical Drug discovery Portfolio Fully diluted 31 March 2021 Net Valuation FX 30 Sep 2021 Valuation % of NAV of £1,152.8m, 171.7p per share, company ownership % value £m (fair value) invested/returned in the period £m change movement value £m (fair value) basis (fair v
Slide 15: Balance sheet: a competitive advantage
Balance sheet: a competitive advantage Provides flexibility and control to take long-term approach Capital pool of £534.9m - £50.8m of capital deployed into the portfolio during the period − Continue to expect to deploy £100m- £175m this financial year £103.4m uncalled commitments across the portfol
Slide 16: Market context
v J Market context aw
Slide 17: Development of the cell and gene therapy field
Development of the cell and gene therapy field Public market sentiment towards cell and gene therapy impacted by inevitable industry challenges in innovative fields of medicine; Syncona view is that field’s promise remains Industry challenge Syncona platform Portfolio position - Potential to deliver
Slide 18: Potential to transform the lives of patients
Potential to transform the lives of patients Kite/Gilead: engineered CAR-T cell therapy for adult relapse / refractory 44% of patients alive at four years post treatment2 3x overall survival rate of current standard of care at 12 Diffuse Large B-cell Lymphoma Designed to halt a disease or reverse it
Slide 19: Cell and gene therapies have the potential to disrupt the market
Cell and gene therapies have the potential to disrupt the market “… By 2025, we predict that the FDA will be approving 10 to 20 cell and gene therapy products a year based on an assessment Approved cell and gene therapies are expected to increase of the current pipeline and the clinical success rate
Slide 20: Summary
Summary
Slide 21: Significant value creation opportunity ahead
Significant value creation opportunity ahead Positive clinical data drives value but is not without risk Increasing value potential Company formation Preclinical Clinical Late Phase I/II and beyond Syncona Generation 1 3.2x c2012 - 2014 Multiple of cost1 Syncona Generation 2 0.8x c2015-2016 Multiple
Slide 22: Summary
Summary Syncona’s platform creates value from the commercialisation of life science innovation CURRENT PORTOLIO ROLLING 10 YEAR TARGETS Period of intensive management of the portfolio supporting companies to navigate clinical development 18 Portfolio companies 2 Companies sold since foundation, aggr
Slide 23: Appendix 1 – Syncona team
Appendix 1 – Syncona team
Slide 24: An expert multi-disciplinary team
An expert multi- Our unique skill set disciplinary team Scientific Commercial Company creation Investment Investment committee Nigel Keen Martin Murphy 1,2 Chris Hollowood 1 Co-founder and Chairman Co-founder and CEO CIO FIET, FCA PhD PhD Purespring ‒ Commercial and company creation ‒ Scientific, co
Slide 25: Appendix 2 – Portfolio companies
Appendix 2 – Portfolio companies
Slide 26: Portfolio company outlook
Portfolio company outlook Strong momentum in the portfolio with near term catalysts Company Status of pipelines Next steps Three programmes across four clinical trials - Progress pivotal study AUTO1 / Adult ALL, Phase Ib data update in Q4 CY2021 with pivotal data in mid CY2022 - Publish clinical dat
Slide 27: Autolus Therapeutics
Autolus Therapeutics Applying a broad range of technologies to build Investment thesis a pipeline of precisely targeted T cell therapies - No CAR-T therapy approved for adult designed to better recognise and attack cancer ALL patients Board Seat 1 Key management team - AUTO1 has a differentiated saf
Slide 28: Freeline Therapeutics
Freeline Therapeutics Seeking to deliver constant high protein expression Key management team Investment thesis levels with curative potential across a broad pipeline of Michael Parini, CEO (former Chief Administrative, Legal and - To deliver therapies for a broad pipeline systemic diseases; opportu
Slide 29: Gyroscope Therapeutics
Gyroscope Therapeutics Global clinical-stage company developing gene therapy Investment thesis beyond rare disease Key management team - Seeking to take application of gene therapy beyond rare diseases to treat Khurem Farooq, Chief Executive (formerly SVP of Immunology and dry AMD sub-retinally Opht
Slide 30: Achilles Therapeutics
Achilles Therapeutics Differentiated cell therapy approach targeting Key management team Iraj Ali, Chief Executive (former Syncona Partner) Investment thesis solid tumours utilising bioinformatics and TILs Karl Peggs, Founder and Chief Medical Officer - TILs have shown convincing efficacy in to targ
Slide 31: Anaveon Therapeutics
Anaveon Therapeutics Exploiting the power of cytokines to orchestrate Investment thesis immune responses by using protein - Developing a selective IL-2 agonist with engineering with the potential to create to improved administration and toxicity create safe and effective treatments for various burde
Slide 32: SwanBio Therapeutics
SwanBio Therapeutics Developing leading-edge gene therapies to Investment thesis deliver dramatic clinical efficacy for the - Gene therapy has the potential to be treatment of neurological diseases transformational in neurology Board Seat 2 (inc. Chair) Key management team - Lead programme targeting
Slide 33: Quell Therapeutics
Quell Therapeutics Engineered cell therapy company addressing Investment thesis Key management team immune dysregulation Iain McGill, CEO (formerly on the Executive Committee and as Head of - Current standard of care for prevention Europe and Rest of World for Jazz Pharmaceuticals) of solid organ tr
Slide 34: OMass Therapeutics
OMass Therapeutics Using novel biochemistry techniques, native mass Investment thesis spectrometry and custom chemistry to deliver novel - Opportunity to develop differentiated medicines against highly validated but inadequately small molecule drugs leveraging a drugged targets, with a focus on immu
Slide 35: Resolution
Resolution Developing macrophage cell therapies to Investment thesis repair inflammatory organ damage, including - An opportunity to create the leading treatment of end-stage chronic liver disease. inflammation-focused macrophage cell therapy business, focusing initially on Key management team treat
Slide 36: Purespring
Purespring Advancing gene therapies for the treatment of Investment thesis chronic renal diseases that are currently poorly - A number of chronic kidney diseases addressed with existing treatments are poorly addressed by existing therapies, which are primarily based Key management team around the lo
Slide 37: Neogene
Neogene Building a differentiated small molecule Investment thesis portfolio based on a unique drug discovery - The company is developing an platform leveraging native Mass Spectrometry. engineered T Cell Receptor (TCR) therapeutic approach for solid Key management team tumours based on a patient’s
Slide 38: Appendix 3 – Sustainability
Appendix 3 – Sustainability
Slide 39: Sustainability
Sustainability - PRI signatory from October 2021 Progress in year so far - Responsible Investment Policy rolled out to majority of portfolio - Syncona Ltd emissions target to be published Ongoing priorities for - First year of TCFD alignment FY22 - Responsible Investment Policy roll-out to full port
Slide 40: The Syncona Foundation
The Syncona Foundation Supporting excellent charities that are meeting pressing needs within society, particularly those that are related to healthcare systems Focused on cancer, neuro-degenerative diseases, £36.4m Donations since 20121 gene therapy. Alongside other health and society related areas